HTG Molecular Diagnostics Participating in WIN 2017 Symposium

Posted: Monday, July 03, 2017


TUCSON, Ariz., June 26, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced its participation in WIN 2017 Symposium, dedicated to Expediting Global Innovation in Precision Cancer Medicine, which is being held in Paris, France on June 26 and 27, 2017. HTG is an industry member of the Worldwide Innovative Networking (WIN) Consortium, whose mission is to rapidly translate personalized cancer medicine discoveries into standards of patient care worldwide. WIN is a non-profit global network of world-class academics, industries and patients’ advocates aiming to transform the practice of oncology and significantly improve survival and quality of life of cancer patients. HTG was actively recruited to the consortium to support gene expression profiling activities of its members, including WIN clinical trials that integrate RNA investigations in the clinical setting.

“The membership of HTG in our organization is a key asset of WIN,” said Dr. Vladimir Lazar, Chief Scientific and Operating Officer of WIN. “HTG’s innovative technologies and cooperation with WIN members has been instrumental to develop a new generation of biomarkers that we expect to use in planned clinical trials.”

“We see great synergy and alignment between the missions of WIN and our company, especially as they relate to improvements in cancer patient care,” stated TJ Johnson, President and Chief Executive Officer of HTG. “We believe the benefits of our HTG EdgeSeq technology, including low sample input and easy to deploy instrumentation, work well with WIN’s innovative clinical trial designs, and we are thrilled to assist in these important programs.”

About HTG:

Headquartered in Tucson, Arizona, the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. In 2013 the company commercialized its first instrument platform and a portfolio of RNA assays that leveraged HTG's original proprietary nuclease protection chemistry. Continuous improvement led to the 2014 launch of the company’s HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.

About WIN Consortium:

The WIN Consortium is a global network of 40 leading organizations from the academic, pharmaceutical, biotechnology and patient advocacy sectors working to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials, the most promising advances in genomic-based cancer research. WIN is a non-governmental, not-for-profit organization headquartered in Paris. For further information visit www.winconsortium.org and www.winsymposium.org

Safe Harbor Statement:

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the benefits of HTG membership in the WIN Consortium. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that WIN clinical trials occur when expected, or at all, the risk that HTG EdgeSeq technology may not provide the anticipated benefits to WIN Consortium members or WIN clinical trials, and the capabilities of HTG products to keep pace with rapidly changing technology and user requirements. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10‑Q for the quarter ended March 31, 2017. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact:

Westwicke Partners
Jamar Ismail
Phone: 415-513-1282
Email: jamar.ismail@westwicke.com

TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: 520-547-2827 x130
Email: tjjohnson@htgmolecular.com

HTG Molecular Diagnostics, Inc.

WIN represents a global collaboration of cancer centers, life science and biotech organizations, pharmaceutical and technology companies, health plans, and not-for-profit organizations.
The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine was initiated in 2010 with leadership from leading cancer centers worldwide. WIN is a non-profit, non-governmental organization headquartered in Paris.

WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.

WIN now includes 35 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.

Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
WIN is comprised of organizations representing all stakeholders in personalized cancer medicine.
WIN enables cross-sector collaborations designed to accelerate the speed and efficacy with which breakthroughs in personalized cancer medicine can be realized and brought to patients worldwide.

Our members include leading academic, pharmaceutical, life science, not-for-profit, health IT, and healthpayer organizations.
Our members include 25 leading academic centers representing 17 countries and four continents, enabling coordinated studies with a global patient population.
The response to a genetically-targeted therapy can vary due to differences in ethnicity and environment. WIN's global studies are designed to identify and account for this variability, enhancing the speed and efficacy with which novel discoveries can be made and brought to patients around the world.

WIN's first trial, WINTHER, is currently being carried out through a collaboration between six academic centers in five countries, with key support from Europe (EUFP7), Fondation ARC, Pfizer and other pharma companies.
WIN prioritizes cross-sector interaction designed to enhance learning across and between continents and healthcare sectors.
WIN Symposia, held annually in Paris, bring together hundreds of leaders representing all stakeholders from around the world in a forum designed to promote the exchange of ideas and information.